View Main Condition: Lung Cancer
Common conditions include: EGFR Positive Lung Cancer, Large-Cell Lung Carcinoma, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma
Heather Wakelee is an Oncologist in Palo Alto, California. Wakelee has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 19 other conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Thymic Epithelial Tumor, Hormone Replacement Therapy (HRT), and Tissue Biopsy. Wakelee is currently accepting new patients.
Zhongxing Liao is a Radiation Oncologist in Houston, Texas. Liao has been practicing medicine for over 41 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Esophageal Cancer, Squamous Cell Lung Carcinoma, and Gamma Knife Radiosurgery. Liao is currently accepting new patients.
Thomas Stinchcombe is an Oncologist and a Hematologist Oncology expert in Durham, North Carolina. Stinchcombe has been practicing medicine for over 28 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 13 other conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Stinchcombe is currently accepting new patients.
Summary: This is a study in adults with advanced solid tumors including non-small cell lung cancer. The study tests the combination of two medicines called BI 754111 and BI 754091 that may help the immune system to fight the cancer. Such medicines are called immune checkpoint inhibitors. The study has two parts. In the first part, doctors want to find out the highest dose of 2 medicines that people with so...
Summary: This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatm...